Prevention and therapy of neutropenia in elderly patients

Giovanni Rosti, Barbara Kopf, Anna Cariello, Manlio Monti, Claudio Dazzi, Giorgio Papiani, Petros Giovanis, Ugo De Giorgi, Maurizio Marangolo

Research output: Contribution to journalArticle


Standard chemotherapy in elderly patients is still nowadays a difficult issue, due to the fact that marrow reserve decrease with age and the results might lead to higher toxicity of otherwise well tolerated regimen and schedule. In the literature, very few data exist of myelosuppression in patients with solid tumors, while more data have been published on non-Hodgkin's lymphoma. The burden of toxicity increase with age, leading to the fact that some patients with curable or sensitive disease do not receive appropriate treatment. One of the ways to try to circumvent neutropenia is the prophylactic use of haematopoietic growth factors with the double aim of maintaining dose-intensity and reducing toxicity. This paper will describe the patterns of marrow toxicity in treating elderly patients with cancer and the role of haematopoietic growth factors.

Original languageEnglish
Pages (from-to)247-253
Number of pages7
JournalCritical Reviews in Oncology/Hematology
Issue number3
Publication statusPublished - Jun 1 2003



  • Chemotherapy
  • Elderly patients
  • Haematopoietic growth factors
  • Toxicity

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Rosti, G., Kopf, B., Cariello, A., Monti, M., Dazzi, C., Papiani, G., Giovanis, P., De Giorgi, U., & Marangolo, M. (2003). Prevention and therapy of neutropenia in elderly patients. Critical Reviews in Oncology/Hematology, 46(3), 247-253.